India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Lawmakers are trying to restore access to GLP-1 weight loss drugs, like Ozempic and Wegovy, after Ohio removed medical ...

Offering a rare glimpse inside the hidden world of rejected insurance claims, new data shows a steady uptick among major ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...

A $4.4 million shortfall in the city’s health insurance trust fund is a result of rising medical costs, including from the classification of drugs that include weight loss ...